CLINICAL TRIALS PROFILE FOR VALGANCICLOVIR HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for VALGANCICLOVIR HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002222 ↗ | A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS | Completed | Hoffmann-La Roche | N/A | 1969-12-31 | The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis. |
| NCT00002377 ↗ | A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes | Completed | Hoffmann-La Roche | Phase 3 | 1997-01-01 | To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population. |
| NCT00006145 ↗ | Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2000-08-01 | Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in people with HIV. |
| NCT00016068 ↗ | Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation | Completed | National Cancer Institute (NCI) | Phase 3 | 2001-01-01 | RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation. |
| NCT00016068 ↗ | Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation | Completed | Fred Hutchinson Cancer Research Center | Phase 3 | 2001-01-01 | RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VALGANCICLOVIR HYDROCHLORIDE
Condition Name
Clinical Trial Locations for VALGANCICLOVIR HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for VALGANCICLOVIR HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for VALGANCICLOVIR HYDROCHLORIDE
Sponsor Name
